BofA update shows where active managers are putting money
Investing.com -- Cognition Therapeutics Inc (NASDAQ:CGTX) stock surged 14% following the announcement of upcoming presentations of Phase 2 study results for its dementia with Lewy bodies (DLB) treatment.
The clinical-stage neurodegenerative disease company revealed that Dr. James E. Galvin will present findings from the Phase 2 ’SHIMMER’ study of zervimesine (CT1812) at the Alzheimer’s Association International Conference on July 29, 2025. Dr. Galvin, who directed the study, is affiliated with the University of Miami Miller School of Medicine.
According to the company, the SHIMMER study demonstrated that zervimesine treatment slowed the progression of DLB symptoms, with meaningful impacts on neuropsychiatric, motor, functional, and cognitive measures. The drug is being developed as a once-daily oral medication for DLB, which affects approximately 1.4 million Americans and is the second most common cause of dementia.
"The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease," stated Dr. Galvin. "My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB."
The company also plans to present results from its Phase 2 ’SHINE’ study in Alzheimer’s disease patients at the same conference. That study showed zervimesine preserved cognitive and functional abilities better than placebo, with particularly strong results in patients with lower levels of p-Tau217 biomarkers.
Currently, no disease-modifying therapeutics are approved for DLB, which typically presents with hallucinations, cognitive impairment, movement disorders, sleep disturbances, and fluctuations in attention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.